Bardoxolone methyl

Overview

Bardoxolone methyl (RTA 402) is an orally active and blood-brain-barrier-penetrant activator of Nrf2 and an inhibitor of SARS-CoV-2 3CL protease . Bardoxolone methyl inhibits SARS-CoV-2 replication in Vero cells with an EC 50 value of 0.29 μM. Bardoxolone methyl increases levels of pNrf2 and HO-1 , inhibits inflammatory mediators like pNFκB and MCP-1. Bardoxolone methyl activates the Nrf2 pathway to enhance antioxidant and anti-inflammatory responses, inhibits viral replication, and improves mitochondrial function. Bardoxolone methyl can be used in research on chemotherapy-induced neuropathic pain (CINP), COVID-19, and chronic kidney disease (CKD).

Application

Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Renal Disease | Products > Disease Areas > Viral Infection | Products > Disease Areas > Pain | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Chronic Kidney Disease | Products > Disease Areas > Infection | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Urogenital Disease | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > Anti-infection | Products > Research Areas > Neurological Disease | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Infection | Products > Signaling Pathways > Keap1-Nrf2 | Products > Signaling Pathways > SARS-CoV | Products > Signaling Pathways > Virus Protease

Product Information

• Catalog No.: HY-13324
• CAS No.: 218600-53-4
• Molecular Formula: C32H43NO4
• Molecular Weight: 505.69
• Purity: 99.66%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.5 mg/mL (4.94 mM); Clear solution
• Availability: In-stock

Source

Original product source